Fulcrum Gains Momentum After Agios Trial Miss
Fulcrum Therapeutics rises as Agios’ RISE UP trial falls short. Analysts say results reduce competition in sickle cell disease and strengthen Fulcrum’s position ahead of new PIONEER data.
/ 1669 items
#XY↓
Raymond James Boosts Palvella Therapeutics to Strong Buy Ahead of Key Phase 2 Data
Raymond James upgrades Palvella Therapeutics to Strong Buy with a new $143 price target, citing strong confidence in upcoming Phase 2 TOIVA readout for QTORIN rapamycin.
Abbott Laboratories Eyes Largest Deal in Decade with Exact Sciences Acquisition
Abbott Laboratories is in talks to acquire Exact Sciences Corp. for ~$16B, marking its biggest healthcare deal of 2025 and largest acquisition in nearly 10 years.
Mizuho Upgrades Relmada Therapeutics, Sees Big Potential in NDV-01
Mizuho upgrades Relmada Therapeutics to Outperform, raising the price target to $10. NDV-01 shows promise in bladder cancer with $2B peak sales potential.
Agios Mitapivat Trial Shows Promise but Misses Key Goals
Agios Pharmaceuticals reports mixed Phase 3 results for mitapivat in sickle cell disease, meeting some endpoints while missing key pain crisis reduction goals.
Tegoprubart Trial: Six Type 1 Diabetes Patients Achieve Insulin Independence Without Toxic Side Effects
Eledon’s (ELDN) tegoprubart helps Type 1 diabetes patients achieve insulin independence after islet transplants without harsh side effects of current medications.